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Abstract
Introduction: MicroRNAs (miRs) are interesting new diagnostic targets that may provide important insights into
the molecular pathogenesis of breast cancer. Here we evaluated, for the first time, the feasibility and clinical utility
of circulating miRs as biomarkers for the detection and staging of breast cancer.
Methods: The relative concentrations of breast cancer-associated miR10b, miR34a, miR141 and miR155 were
measured in the blood serum of 89 patients with primary breast cancer (M0, n = 59) and metastatic disease (M1,
n = 30), and 29 healthy women by a TaqMan MicroRNA Assay.
Results: The relative concentrations of total RNA (P = 0.0001) and miR155 (P = 0.0001) in serum significantly
discriminated M0-patients from healthy women, whereas miR10b (P = 0.005), miR34a (P = 0.001) and miR155 (P =
0.008) discriminated M1-patients from healthy controls. In breast cancer patients, the changes in the levels of total
RNA (P = 0.0001), miR10b (P = 0.01), miR34a (P = 0.003) and miR155 (P = 0.002) correlated with the presence of
overt metastases. Within the M0-cohort, patients at advanced tumor stages (pT3 to 4) had significantly more total
RNA (P = 0.0001) and miR34a (P = 0.01) in their blood than patients at early tumor stages (pT1 to 2).
Conclusions: This pilot study provides first evidence that tumor-associated circulating miRs are elevated in the
blood of breast cancer patients and associated with tumor progression.
Introduction
The development of breast cancer is a complex multi-
step process associated with numerous genetic altera-
tions, downregulation of tumor suppressor genes,
upregulation of oncogenes and early hematogeneous dis-
semination of tumor cells [1-3]. Accordingly, the eluci-
dation of the molecular mechanisms in breast cancer
has been the subject of extensive research over the past
decade. The search for sensitive, non-invasive markers
that represent tumor-associated changes in the periph-
eral blood might facilitate early detection of breast can-
cer as well as monitoring of tumor progression and
treatment responses.
MicroRNAs (miRs) are small, non-coding RNA mole-
cules and consist of approximately 22 nucleotides. MiRs
modulate post-transcriptionally the expression of
numerous genes, such as of tumor suppressor genes, by
binding sequence specifically to their target mRNA and
inhibiting their translation into polypeptides. Moreover,
miRs are involved in the regulation of different cellular
processes, for example, apoptosis, hematopoietic cell dif-
ferentiation, metabolism, neural development and
metastasis [4,5]. The importance of miRs in the regula-
tion of these processes has been documented by the
results obtained in knockout mice. Knocking out the
enzyme Dicer, responsible for the maturation of miRs,
caused death of a mouse embryo [6]. As half of human
miRs are located in fragile chromosomal regions harbor-
ing DNA amplifications, deletions or translocations,
their expression is frequently deregulated during tumor
development, which contributes to tumor progression
[7].
Apart from their release of DNA and RNA, apoptotic
and necrotic cells of the primary tumor also discharge
miRs into the blood circulation. Protected from the
degradation by endogenous RNase activity, miRs
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circulate in a remarkably stable form in human blood
[8]. In the year 2008, extracellular serum miRs were for
the first time described for patients with diffuse B cell
lymphoma [9]. Although numerous publications have
reported on the elevated levels of circulating nucleic
acids in the blood of breast cancer patients [10-13],
there are only a few publications dealing with circulating
miRs in peripheral blood of breast cancer patients
[7,14-16]. To date, most studies describe the profile of
miR expression in breast cancer cell lines and primary
tumor tissue [7].
In primary and metastatic breast carcinomas, high
transcript levels of miR10b were detected and associated
with tumor progression. Overexpression of miR10b in a
non-metastatic breast cancer cell line induced invasion
and metastasis [17]. Knockdown of miR34a by small
interfering RNA significantly suppressed proliferation in
the breast cancer cell line MCF-7, indicating that
miR34a overexpression may be an acquired feature dur-
ing carcinogenesis and support cell proliferation in
breast tumors [18]. Consistent with its role in regulation
of epithelial to mesenchymal transition (EMT), an essen-
tial early step in metastasis, the expression of the
miR200 family, including miR200a, miR200b, miR200c,
miR141 and miR429, was found to be lost in invasive
breast cancer cell lines with a mesenchymal phenotype.
Expression of these miRs was also lost in areas of meta-
plastic breast cancer specimens lacking the adhesion
molecule E-cadherin [19]. Knockout mice, which do not
express miR155, showed that this miR played an impor-
tant role in the immune system. In Hodgkin’s lym-
phoma, diffuse B cell lymphoma and breast cancer
miR155 was highly expressed [20,21].
In summary, miRs are involved in the molecular
pathogenesis of malignant tumors including breast can-
cer, and they might represent novel diagnostic markers.
To assess the potential of serum miRs as biomarkers in
breast cancer, we here examined the transcript levels of
miR10b, miR34a, miR141 and miR155 in blood serum
of breast cancer patients.
Material and methods
Patient design and healthy controls
Patients have been invited to take part in a multicenter
study (SUCCESS) and attending local hospitals in the
network of Ludwig Maximilians University of Munich.
During September 2005 to July 2006, blood serum was
taken from 59 patients with primary breast cancer about
29 days after surgery before initiation of adjuvant ther-
apy. The median follow-up time of this patient subgroup
was three years (range 1.6 to 4.2 years). During January
to April 2009, blood serum from patients with meta-
static breast cancer (n = 30) was collected 1 to 13 years
after surgery of the primary tumor. All patients analyzed
had histologically proven epithelial cancer and no
known comorbidities. Metastatic spread in M0 patients
was excluded by chest radiology, liver ultrasound scan
and bone scan. Additionally, 29 healthy women with no
history of cancer and in good health based on self-
report were recruited as controls. All patients and
healthy controls gave their informed consent. The exam-
ination of all samples was approved by the local ethics
review boards. Table 1 summarizes the clinical and his-
topathological factors of the breast cancer patient
cohort.
Cell culture
For investigations of miR expression the breast cancer
cell lines MDA-MB-231 and GI-101 and the micrometa-
static breast cancer cell lines BC-M1 and BC-S1 were
used. MDA-MB-231 and GI-101 were cultured in
DMEM (Invitrogen, Karlsruhe, Germany) supplemented
with 10% FCS (fetal calf serum; PAA Laboratories,
Cölbe, Germany), 2 mMol L-glutamin (Invitrogen) and
200 U/mL antibiotic-antimycotic solution (PAA). Micro-
metastatic cells were cultured in RPMI (Invitrogen) with
2 mMol L-glutamin (Invitrogen), 200 U/mL antibiotic-
antimycotic solution (PAA), 1× Insulin-Transferrin-Sele-
nium-A (Gibco, Eggenstein, Germany), 50 ng/mL
human EGF (epidermal growth factor; Macs Miltenyi
Biotec, Bergisch Gladbach, Germany) and 10 ng/mL
human bFGF (basic fibroblast growth factor; Macs Mil-
tenyi Biotec).
Extraction of total RNA
For isolation of total RNA from human blood serum
and cultured cell lines, the mirVana PARIS kit (Ambion,
Darmstadt, Germany) was used. Four hundred μL of
serum samples and 1 × 106 lysed cells were incubated
with an equal volume of Denaturation Solution for five
minutes on ice. According to the manufacturer´s proto-
col, the RNA extraction was performed by acid-phenol:
chloroform, and the precipitation was carried out by
ethanol and a filter cartridge. The extracted RNA was
eluted in 100 μL of preheated Elution Solution and mea-
sured on a NanoDrop ND-1000 Spectrophotometer
(Thermo Scientific, Wilmington, DE, USA). The RNA
samples were immediately stored at -80°C and within
few days converted into cDNA.
Conversion of total RNA into cDNA
Reverse transcription was performed by the TaqMan
MicroRNA Reverse Transcription Kit (Applied Biosys-
tems, Darmstadt, Germany). The 10 μL-reverse tran-
scription reaction contained 0.1 μL 100 mM dNTPs,
0.66 μL MultiScribe Reverse Transcriptase (50 U/μL), 1
μL 10× Reverse Transcription Buffer, 0.13 μL RNase
Inhibitor (20 U/μL), nuclease-free water and 3.33 μL or
Roth et al. Breast Cancer Research 2010, 12:R90
http://breast-cancer-research.com/content/12/6/R90
Page 2 of 8
1 μL RNA derived from human serum or cultured cells,
respectively. On a MJ Research PTC-200 Peltier Ther-
mal Cycler (Global Medical Instrumentation, Ramsey,
Minnesota, USA) the reaction was carried out at 16°C
for 30 minutes, 42°C for 30 minutes and 85°C for 5
minutes.
Preamplification of miR141 and miR16 cDNA
Due to the low expression of miR141, a preamplification
of its cDNA was performed. To effectively normalize
the expression data of miR141, cDNA of the reference
miR16 was also preamplified. Both cDNAs were pream-
plified in 7.5 μL Taq PCR Mastermix and 0.75 μL 20 ×
TaqMan MiRNA Assay mix by using the Taq PCR Mas-
termix Kit (Qiagen, Hilden, Germany). The PCR was
run on a MJ Research PTC-200 Peltier Thermal Cycler
(Global Medical Instrumentation): 1 cycle at 95°C for 5
minutes, 15 cycles at 95°C for 20 s, 60°C for 20 s and
72°C for 20 s, and a terminal cycle at 72°C for 5
minutes.
Quantitative real-time PCR of miR10b, miR34a, miR141
and miR155
For quantitative real-time PCR, the miR-specific Taq-
Man MicroRNA Assays (Applied Biosystems) for miR16
(reference miR), miR10b, miR34a, miR141 and miR155
were used. In a 10 μL-reaction, 1 μL cDNA or 3 μL pre-
amplified cDNA were mixed with 5 μL TaqMan Univer-
sal PCR Master Mix No AmpErase UNG and 0.5 μL
miR-specific TaqMan MicroRNA Assay Mix on a twin-
tec real-time PCR plate (Eppendorf, Hamburg,
Germany). The quantitative real-time PCR reaction was
performed at 95°C for 10 minutes and in 40 cycles at 95°C
for 15 s and 60°C for 60 s on a Mastercycler Realplex
Table 1 Patients’ characteristics at the time of primary diagnosis of breast cancer and correlations of the serum RNA
and miR values with these parameters
Parameters Patients (%) Total RNA miR10b miR34a miR141 miR155
Total 89 Median ± Standard Deviation
Age 56 years
(range 31 - 82 years)
Distant metastasis
£M0 59 a 5.4 ± 3.5 b 0.1 ± 0.2 c 0.4 ± 0.6 0.00 ± 16.1 d 2.4 ± 1.6
$M1 30 a 2.6 ± 1.5 b 0.4 ± 0.6 c 1.8 ± 2.7 0.0 ± 0.3 d 1.5 ± 0.9
#Tumor stage
pT1-2 27 (45.8) e 3.6 ± 3.4 0.2 ± 0.2 f 0.2 ± 0.6 0.0 ± 0.0 2.2 ± 1.9
pT3-4 32 (54.2) e 7.3 ± 2.9 0.1 ± 0.1 f 0.6 ± 0.5 0.0 ± 0.0 3.1 ± 1.3
#Lymph node metastasis
N0 21 (35.6) 7.3 ± 5.0 0.3 ± 0.2 0.6 ± 0.4 0.0 ± 0.01 2.2 ± 1
N1-3 38 (64.4) 5.3 ± 2.1 0.1 ± 0.2 0.3 ± 0.7 0.0 ± 0.01 2.6 ± 1.9
#Grading
II 26 (44.1) 3.4 ± 2.7 0.1 ± 0.3 0.3 ± 0.2 0.0 ± 0.02 1.6 ± 1
III 33 (55.9) 5.5 ± 3.8 0.1 ± 0.2 0.5 ± 0.7 0.0 ± 0.05 2.9 ± 1.7
#Estrogen receptor status
positive 37 (62.7) 5.0 ± 3.3 0.1 ± 0.3 0.3 ± 0.3 0.0 ± 0.01 2.1 ± 1.2
negative 22 (37.3) 5.4 ± 4.4 0.2 ± 0.2 0.4 ± 0.7 0.0 ± 0.1 2.9 ± 1.8
#Progesterone receptor status
positive 33 (55.9) 5.0 ± 3.1 0.1 ± 0.3 0.3 ± 0.2 0.0 ± 0.05 2.1 ± 1.1
negative 26 (44.1) 5.4 ± 3.9 0.1 ± 0.2 0.4 ± 0.7 0.0 ± 0.02 2.9 ± 1.8
#HER2
positive 30 (53.6) 3.9 ± 2.3 0.2 ± 0.3 0.3 ± 0.6 0.0 ± 0.01 2.4 ± 1.9
negative 26 (46.4) 6.0 ± 4.4 0.1 ± 0.2 0.6 ± 0.5 0.0 ± 0.1 2.9 ± 1.3
Number of CTC¥
positive 47 (82.5) 2.9 ± 5.6 0.3 ± 0.3 0.5 ± 0.6 0.0 ± 0.0 2.2 ± 0.9
negative 10 (17.5) 5.5 ± 2.9 0.1 ± 0.2 0.3 ± 0.4 0.0 ± 0.0 2.5 ± 1.7
ap = 0.0001, bp = 0.014, cp = 0.003, dp = 0.002, ep = 0.0001, fp = 0.01
£M0, patients with localized breast cancer
$M1, patients with metastatic breast cancer
#of M0 patients
¥CTC, circulating tumor cells
p values as determined by Mann and Whitney-U test.
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(Eppendorf). Melting curve analyses were performed to
verify the specificity and identity of PCR products.
The obtained data of the miR expression levels were
calculated and evaluated by the ΔCt method as follows:
ΔCt = mean value Ct (reference miR16) - mean value
Ct (miR of interest). The relative expression of miR of
interest corresponded to the 2^(ΔCt) value.
As recommended by the manufacturer (Applied Bio-
systems), miR16 has been chosen as reference for nor-
malization of the expression levels of our miR panel. To
effectively normalize the expression data of miR10b,
miR34a, miR141 and miR155, we analyzed the miR16
expression levels and found that the levels remained
relatively constant across the serum samples. We calcu-
lated a mean value of 21.12, 22.23, and 21.17 with a
standard deviation of 2.10, 2.12 and 0.98 for the sub-
groups of M0 patients, M1 patients and healthy women,
respectively.
Statistical analysis
The statistical analyses were performed using the SPSS
software package, version 18.0 (SPSS Inc. Chicago, IL,
USA). The chi square or two-tailed Fischer´s exact test
was used to identify potential associations of miR con-
centrations in blood serum with the clinical and histo-
pathological risk factors of the breast cancer patients.
For nonparametric comparisons, univariate analyses of
the Mann Whitney-U test of two independent variables
and bivariate analyses of the Spearman-Rho test were
used. Kaplan-Meier plots were drawn on to estimate
overall survival and recurrence, and the Log rank test
was applied for statistical analyses. Missing data were
handled by pairwise deletion. A P-value ≤0.05 was con-
sidered as statistically significant. All P-values are two-
sided.
Results
Expression pattern of miR10b, miR34a, miR141 and
miR155 in breast cancer cell lines
Before examining the signature of the four miRs
(miR10b, miR34a, miR141 and miR155) in human
blood, we analyzed their expression patterns in the
widely used breast cancer cell lines MDA-MB-231 and
GI-101 as well as in the micrometastatic cell lines BC-
M1 and BC-S1 which were established from dissemi-
nated tumor cells present in the bone marrow of breast
cancer patients without overt distant metastases [22].
Interestingly, BC-M1 and BC-S1 cells co-express cyto-
keratin and vimentin consistent with an EMT-like inva-
sive phenotype as well as other cancer stem cell
characteristics [23,24].
We quantified the relative expression of these miRs by
determining the low cycle threshold (Ct) values. As
shown in Figure 1A-D, the relative values of the miRs in
MDA-MB-231 and GI-101 differed from those in the
micrometastatic cell lines. Compared with the low
Figure 1 MiR expression in breast cancer cell lines as determined by quantitative real-time PCR. Basal expression levels of miR10b (A),
miR34a (B), miR141 (C) and miR155 (D) in breast cancer cell lines MDA-MB-231 and GI-101, and micrometastatic breast cancer cell lines BC-M1
and BC-S1. The relative transcript levels of the miRs were determined by the low cycle threshold (Ct) values.
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values in MDA-MB-231 and GI-101 cells, the transcript
levels of miR10b (Figure 1A), miR34a (Figure 1B) and
miR155 (Figure 1D) were significantly upregulated in
the micrometastatic breast cancer cells BC-M1 and
BC-S1. MiR141 expression was clearly upregulated in
MBD-MB-231, and GI-101 cells, whereas it was nearly
abolished in the micrometastatic cells (Figure 1C).
Profiling of total RNA
In the box plot of Figure 2, the relative quantification of
circulating total RNA, miR10b, miR34a, miR141 and
miR155 in blood serum of 29 healthy individuals and 89
patients with breast cancer (M0, n = 59 and M1, n =
30) are depicted. To determine the differences in the
relative expression profiles, we performed univariate
analyses of the Mann Whitney-U test.
As shown in Figure 2, M0 patients had significantly
higher levels of circulating total RNA in their blood
(normalized Ct values), which was taken approximately
four weeks after surgery, than healthy individuals (P =
0.0001). Counter to expectation, M1 breast cancer
patients had similar RNA concentrations to healthy indi-
viduals. M0 patients had on average 2.0-fold higher
median values of RNA than M1 patients and healthy
controls (P = 0.0001). In addition, we also analyzed
paired serum samples taken pre- and post-operatively
from 10 breast cancer patients. Our data showed similar
RNA levels before and four weeks after surgery (P =
0.375, data not shown).
In respect to the miRs, the median values of miR155
of both subgroups M0 and M1 were 2.7-fold (P =
0.0001) and 1.6-fold (P = 0.008) increased in comparison
to healthy women. In contrast, the values of miR10b (4-
fold, P = 0.005) and miR34a (4.5-fold, P = 0.001) could
only discriminate M1 patients, but not M0 patients,
from healthy individuals. In M0 and M1 patients, their
relative yields of miR141 did not differ significantly
between healthy women and women with breast cancer
(Figure 2).
Correlation of circulating total RNA and miRs in serum of
breast cancer patients with clinical and histopathological
factors
We compared the relative concentrations of circulating
total RNA, miR10b, miR34a, miR141 and miR155 in
blood serum of the 89 breast cancer patients with their
clinical and histopathological data. For these statistical
evaluations, the Mann and Whitney-U test of the non-
parametric comparison of two independent variables
and Log rank test were used (Table 1). As shown in
Table 1 and Figure 2, the transcript levels of miR10b (P
= 0.014) and miR34a (P = 0.003) were significantly
higher in serum of M1 patients than M0 patients,
whereas the levels of miR155 (P = 0.002) and total RNA
(0.0001) in M1 patients were lower than in M0 patients.
Moreover, high values of total serum RNA (P = 0.0001)
and miR34a (P = 0.01) correlated with advanced tumor
stages within the subgroup of 59 M0 patients (Table 1).
In addition, we correlated the values of total RNA and
miRs with the number of mononuclear blood cells of
M0 patients, because leukocytes could also be a source
for the release of these RNAs. Unfortunately, no data on
the number of leukocytes were available for M1 patients.
Surprisingly, M0 patients at early tumor stages had sig-
nificantly more leukocytes in their blood than patients
at advanced tumors (P = 0.016). No significant relation-
ship of the number of leukocytes to the RNA and miR
values could be detected.
The statistical assessments between the concentrations
of miRs and the other clinical and histopathological data
as well as the number of circulating tumor cells (CTC)
did not reach any statistical significance (Table 1). The
number of CTC was only determined in blood of M0
patients. Within this subgroup, 57 of 59 patients were
analyzable for CTC but only 10 (18%) patients had CTC
in their blood. This low number of CTC-positive
patients impeded an accurate statistical analysis.
Kaplan-Meier and Log-rank models were used to
assess the prognostic potential of miR levels in serum of
breast cancer patients. The median follow-up time was
three years (range 1.6 to 4.2 years). Median expression
levels were used for grouping the serum samples
according to low and high expression. The serum levels
of miR141 could not discriminate breast cancer patients
from healthy women but the association with the clini-
cal outcome reached borderline significance (P = 0.1 for
progression-free survival in M1 patients and P = 0.06
Figure 2 Levels of total RNA and miRs in blood of breast
cancer patients and healthy controls. The box plot and the
additionally integrated box plot of miR141 show the different,
relative amounts of total RNA, miR10b, miR34a, miR141 and miR155
which circulate in blood of healthy individuals (n = 29), M0 patients
(n = 59) and M1 patients (n = 30). The relative transcript levels of
miRs were determined by the low cycle threshold (Ct) values. As
determined by Mann and Whitney-U test, the significant P-values of
the statistical evaluations of serum RNA and miR levels are indicated
above the blots.
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for recurrence-free survival in M0 patients). The mea-
surements of the other serum miRs were not associated
with either diagnosis or progression of breast cancer.
Discussion
Emerging evidence indicates that the deregulation of
miRs might play a crucial role in breast carcinogenesis
[25]. However, their precise role in promoting breast
cancer progression and metastasis remains under inves-
tigation. Previous studies scrutinizing the signature of
miRs in tumor patients have mainly been carried out by
using tumor tissues. To date, only a handful of publica-
tions have dealt with circulating miRs in blood of breast
cancer patients [7,14-16]. Based on their regulation of
relevant target genes [19,21,26,27], we assembled a set
of four miRs (miR10b, miR34a, miR141 and miR155)
and examined whether their expression profile in blood
serum was associated with diagnosis and progression of
breast cancer. To our best knowledge, only miRNA10b,
miR141 and miR155 have been measured in blood
serum so far by other groups [9,14-16] including miR-
NA10b and miR155 in breast cancer [7,15,16].
In the present study, we demonstrated that cell-free
serum total RNA and miR155 in M0 patients as well as
miR10b, miR34a and miR155 in M1 patients may discri-
minate breast cancer patients from healthy individuals.
Whereas M0 patients at advanced tumor stages had dra-
matically more RNA in their blood than patients at early
tumor stages, M1 patients with overt distant metastases
surprisingly displayed lower levels of RNA. This obser-
vation cannot be explained by a higher cell turnover in
the advanced tumors of M0 patients because these
tumors were resected four weeks before taking the
blood samples for miR analysis. Notably, because we
collected the serum samples postoperatively, we can not
exclude that serum RNA may also stem from other tis-
sue sources, such as mononuclear blood cells, CTC or
occult micrometastases. However, the statistical evalua-
tions of the number of leukocytes showed no association
with the serum RNA concentrations in M0 patients, and
an inverse correlation with increasing tumor stages.
Since only 10 M0 patients had CTC in their blood, a
meaningful statistical comparison between the CTC and
RNA data was not possible. However, we did not even
observe a tendency of higher RNA and miR levels in
serum of CTC-positive M0 patients. These findings indi-
cate that the bulk of circulating RNA may probably not
stem from mononuclear blood cells, and the contribu-
tion of CTC remains questionable.
The kinetics and metabolism of circulating RNA has
not yet been clearly elucidated, and a possible caveat of
our study results might be that our blood serum sam-
ples were collected approximately four weeks after sur-
gery (that is, before initiation of adjuvant therapy),
which might limit their use for diagnostic purposes. To
address this important concern, we analyzed paired
serum samples taken pre- and postoperatively from 10
breast cancer patients. Our data showed similar RNA
levels before and four weeks after surgery suggesting
that the serum RNA levels did not decrease significantly
after surgery of the primary breast tumor.
Considering the particular miRs in blood serum of our
breast cancer patient cohort, increasing concentrations
of miR10b and miR34a significantly correlated with the
occurrence of overt metastasis. In respect to miR10b,
early studies detected this miR to be down-regulated in
breast tumor tissue compared with normal breast tissue
[28,29]. However, in a recent study using plasma and
serum, the expression of circulating miR10b did not dif-
fer significantly between a breast cancer cohort and
healthy controls, but significantly higher levels were
observed in cancer patients with ER (estrogen receptor)-
negative disease than in those with ER-positive breast
cancer [16]. Our analyses on serum miR10b support the
studies of Ma et al. who reported that miR-10b specifi-
cally played a role in the metastatic process but not in
primary tumor development. They found this miR to be
highly expressed in metastatic breast cancer cells, and
its overexpression initiated invasion and metastasis in a
combination of mouse and human cell models by indir-
ectly activating the pro-metastatic gene RhoC [17].
With regard to miR34a, discrepant data on the expres-
sion of this miR in diverse tumor entities have been
described. It was reported that miR34a was downregu-
lated in non-small cell lung carcinomas, pancreas tumor
cell lines, colon carcinomas and primary neuroblastomas
[27,30]. In contrast, Dutta et al. detected a high inci-
dence of miR34a overexpression in various tumor types
and undetectable expression in only poorly differentiated
gastric adenocarcinomas and renal cell carcinomas. In
the majority of carcinomas they perceived the participa-
tion of miR34a in cell proliferation [18]. Consistent with
the data of Dutta et al. [18], we detected high miR34a
levels in the blood of our breast cancer cohort, in parti-
cular in patients with advanced tumor stages and meta-
static disease.
In addition, we detected significantly lower serum
levels of miR155 in M1 than in M0 patients, but both
subgroups had significantly higher miR155 levels than
healthy individuals. Our findings are in contrast to
another study showing that transcript levels of circulat-
ing miR155 in blood did not differ significantly between
breast cancer and healthy control cohorts [16]. Using
primary breast cancer tissues and epithelial cells, Kong
et al. observed that miR155 may play an important role
in the TGFb-induced EMT, cell migration and cell inva-
sion by targeting the small G-protein RhoA. They indi-
cated that it might be a potential therapeutic target for
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breast cancer intervention [21]. Moreover, circulating
miR155 was shown to be differentially expressed in the
sera of women with hormone-sensitive and -insensitive
breast cancer. Women with progesterone receptor-posi-
tive tumors had a higher miR155 expression than
patients with tumors that were progesterone receptor-
negative [15]. In our breast cancer cohort, we did not
observe different serum miR155 levels between hormone
receptor-positive and -negative patients. This discre-
pancy may mainly be explained by the small number of
patients analyzed in that report.
MiR141 expression was reported to be associated with
cancer progression in breast cancer [31]. Our present
findings showed that although the levels of miR141 did
not markedly change in the blood of patients with meta-
static disease in comparison to patients with primary
breast cancer, the quantification of the serum miR141
concentrations might have a prognostic value in particu-
lar in node-negative patients. To sustain this potential
role of miR141 as prognostic marker, additional results
of future prospective studies with more patients and
longer follow-up periods are needed.
Finally, we assessed the transcript levels of the four
miRs in tumor and micrometastatic cell lines. In tumor
cell lines, the concentrations of the four miRs differed
strikingly from those in the micrometastatic tumor cell
lines [24]. Comparing the miR profiles of the cell lines
with those observed in the blood of breast cancer
patients revealed that the profile of the micrometastatic
cell lines was nearly congruent with that in the blood of
M1 patients, whereas the profiles of the other tumor
cell lines were not concordant with those in the patient´
s blood. Thus, the micrometastatic cell lines might be
good models for future functional analyses.
Conclusion
The significant increase of miR10b, miR34a and miR155
concentrations in the peripheral blood of breast cancer
patients and the observed associations with tumor pro-
gression suggest a potential clinical utility of circulating
miRs as a new class of future biomarkers.
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